

PRESS RELEASE

**Mark Fouquet co-opted to Guerbet Board of Directors
to replace Jacques Biot**

Villepinte, 13 January 2014

The Board of Directors of Guerbet, an international pharmaceutical group specialized in medical imaging, has co-opted Mark Fouquet to the Board for the remaining term of office of Jacques Biot.

Jacques Biot resigned from the Board due to the incompatibility of his appointment as Executive President of the Ecole Polytechnique with the exercising of his functions as company director.

The co-opting of Mark Fouquet will be submitted for ratification at Guerbet's next General Meeting of Shareholders on 23 May 2014.

The career of Mark Fouquet, 54 years of age, the son-in-law of Michel Guerbet, has been spent in the financial sector, in France and internationally. He has been Company Secretary of MGF Easybike, a company for which he assists with and sets up industrial and financial partnerships, since 2011.

Guerbet's Board of Directors has nine members:

- Marie-Claire Janailhac-Fritsch, Chairman
- Marion Barbier
- Jean-Jacques Bertrand
- Vincent Dagommer
- Olivier Guerbet
- Yves L'Epine
- Mark Fouquet
- Christian Louvet
- Claire Massiot-Jouault

About Guerbet

To promote the discovery of new products and ensure its future growth, Guerbet devotes significant resources to research and development every year (approximately 10% of sales). Guerbet (GBT) is listed on NYSE Euronext Paris (Eurolist Compartment B – Mid Caps) and had sales of € 403 million in 2012 with a total workforce of 1,400 employees including 1,000 in France.

Guerbet is a member of G5 Health, an industry association of major French health and life sciences companies.

For additional information about Guerbet please go to www.guerbet.com

Press contacts:

Anne-Laure Delasalle, Communications Director

Tel: + 33 (0)1 45 91 50 03

anne-laure.delasalle@guerbet-group.com